{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:56:12Z","timestamp":1763016972091},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,8,31]],"date-time":"2009-08-31T00:00:00Z","timestamp":1251676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The safety and efficacy of the combination clofarabine\/cyclophosphamide\/etoposide were evaluated in children with advanced acute lymphoblastic leukaemia (ALL). The study enrolled 25 paediatric patients (median age 12\u00b75\u2003years) with either refractory (<jats:italic>n<\/jats:italic>\u2003=\u200317; 68%) or multiple relapsed (<jats:italic>n\u2003<\/jats:italic>=\u20038; 32%) ALL to receive clofarabine 40\u2003mg\/m<jats:sup>2<\/jats:sup>, cyclophosphamide 400\u2003mg\/m<jats:sup>2<\/jats:sup> and etoposide 150\u2003mg\/m<jats:sup>2<\/jats:sup>, daily for 5 consecutive days. No patient died from treatment\u2010related complications. The most common adverse events were febrile neutropenia, mucositis and reversible liver toxicity; no case of liver veno\u2010occlusive disease was reported. The overall remission rate was 56%: 13 patients (52%) achieved complete remission (CR) and one (4%) CR without platelet recovery (CRp). In seven of the 13 (54%) patients achieving CR, remissions were of sufficient duration to allow patients to receive allogeneic haematopoietic stem cell transplantation. The probability of CR\/CRp was greater in the 17 patients with B cell precursor ALL than in the eight with T\u2010ALL (76% vs. 12%, respectively, <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0\u00b701). The 18\u2010month overall survival probability was 39% and 0% in patients who did or did not respond to the treatment, respectively (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0\u00b701). These data suggest that the clofarabine\/cyclophosphamide\/etoposide regimen is well tolerated and can induce clinical response in a relevant proportion of children with refractory\/multiple relapsed ALL.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07882.x","type":"journal-article","created":{"date-parts":[[2009,8,31]],"date-time":"2009-08-31T08:36:55Z","timestamp":1251707815000},"page":"371-378","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Clofarabine, cyclophosphamide and etoposide as single\u2010course re\u2010induction therapy for children with refractory\/multiple relapsed acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"147","author":[{"given":"Franco","family":"Locatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M.","family":"Testi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ester","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Bertaina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Merli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Giraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Parasole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Barberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06527.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04584.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2786"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401963"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056754"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1031"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.4.671"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1933"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124602"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2142"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six\u2010year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL\u2010REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze G.","year":"1991","journal-title":"Blood"},{"issue":"18","key":"e_1_2_7_14_1","article-title":"A phase I study of clofarabine in combination with cyclophosphamide and etoposide: a new regimen in pediatric patients with refractory or relapsed acute leukemia","volume":"25","author":"Hijiya N.","year":"2007","journal-title":"Journal of Clinical Oncology (ASCO Meetings Abstracts)"},{"key":"e_1_2_7_15_1","article-title":"Durable remissions observed in a phase I\/II study of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute leukemia","volume":"112","author":"Hijiya N.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2122"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8554"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.031"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701545644"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-081364"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2804"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.11.002"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027714"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-112920"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.227"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.411"},{"key":"e_1_2_7_27_1","first-page":"21","article-title":"Purine and pyrimidine nucleoside analogs","volume":"19","author":"Plunkett W.","year":"2001","journal-title":"Cancer Chemotherapy and Biological Response Modifiers"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_7_29_1","first-page":"427","article-title":"Outcome of very late relapse in children with acute lymphoblastic leukemia","volume":"89","author":"Rizzari C.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.18"},{"key":"e_1_2_7_31_1","first-page":"5953","article-title":"Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study","volume":"46","author":"Spriggs D.R.","year":"1986","journal-title":"Cancer Research"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.1.74"},{"key":"e_1_2_7_33_1","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4\u2010hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi T.","year":"2001","journal-title":"Clinical Cancer Research"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07882.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07882.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:01:37Z","timestamp":1697454097000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07882.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07882.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07882.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,12]]},"assertion":[{"value":"2009-10-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}